Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008173 | 1.00 | CCR1 (0.40) | CCR1BTKKCNH2 | |
| SCHEMBL27800459 | 0.84 | KCNH2 (0.35) | BTKKCNH2 | |
| SCHEMBL2928608 | 0.79 | CCR1 (0.40) | CCR1BTK | |
| SCHEMBL9069711 | 0.79 | CHRNB2 (0.37) | BTKKCNH2 | |
| SCHEMBL11340426 | 0.77 | KCNH2 (0.56) | BTKKCNH2 | |
| SCHEMBL245158 | 0.77 | CCR1 (0.55) | CCR1KCNH2 | |
| SCHEMBL6273480 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL24618685 | 0.76 | KCNH2 (0.35) | BTKKCNH2 | |
| SCHEMBL29898877 | 0.76 | HRH1 (0.42) | BTKKCNH2 | |
| SCHEMBL25607561 | 0.76 | KCNH2 (0.46) | BTKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111383910-B | Substrate processing method and substrate processing system | 东京毅力科创株式会社 | 2024-07-16 | — | — | CN | disclosed |
| US-11538693-B2 | Substrate processing method and substrate processing system | TOKYO ELECTRON LIMITED (JP) | 2022-12-27 | — | — | US | disclosed |
| CN-111383910-A | Substrate processing method and substrate processing system | 东京毅力科创株式会社 | 2020-07-07 | — | — | CN | disclosed |
| US-20200211857-A1 | SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING SYSTEM | TOKYO ELECTRON LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| CN-101214248-A | Triazolo[4,5-d] pyrimidine derivatives and their application as purinergic receptor antagonists | VERNALIS RES LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
| CN-1496262-A | Triazolo [4, 5-d ] pyrimidine derivatives and their use as purinergic receptor antagonists | О | 2004-05-12 | — | — | CN | disclosed |
| EP-1392312-A1 | TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002055083-A1 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | CCR1 485/4885BTK 3883/4885KCNH2 716/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | CCR1 538/4885BTK 3221/4885KCNH2 939/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | CCR1 348/4885BTK 3400/4885KCNH2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.